Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views

被引:10
|
作者
Wang, Yishen [1 ]
Bajorek, Beata [1 ,2 ]
机构
[1] Univ Technol Sydney, Grad Sch Hlth Pharm, Sydney, NSW 2007, Australia
[2] Royal N Shore Hosp, Dept Pharm, Sydney, NSW, Australia
关键词
Atrial fibrillation; Australia; Decision making; DOACs; Health professionals; Novel oral anticoagulant; Stroke prevention; Warfarin; HEART RHYTHM ASSOCIATION; ORAL ANTICOAGULANTS; EUROPEAN-SOCIETY; OLDER PATIENTS; MANAGEMENT; WARFARIN; THERAPY; RISK; PRESCRIPTION; GUIDELINES;
D O I
10.1007/s11096-016-0329-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background For stroke prevention in patients with atrial fibrillation (AF), the decision-making around antithrombotic therapy has been complicated by older age, multiple comorbidities, polypharmacy and the different pharmacological properties of warfarin and the nonvitamin K antagonist oral anticoagulants (NOACs). The complexity of decision-making has been associated with a reluctance by health professionals to use antithrombotic therapy, leading to poor clinical outcomes. In order to improve stroke prevention in patients with AF, the contemporary perspectives of health professionals on the decision-making around antithrombotic therapy needs exploration. Objective To elicit emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Setting Sydney metropolitan area of New South Wales, Australia. Method A qualitative study based on face-to-face interviews was conducted from August to October 2014. Seven pharmacists, seven specialists, six general practitioners and six nurses practising in the Sydney metropolitan area and managing antithrombotic therapy for AF were interviewed until theme saturation was achieved in each subgroup. Interview transcripts were analysed using manual inductive coding. Main outcome measure Emerging themes describing health professionals' perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Results Three overarching themes emerged. (1) Comprehensive assessment is necessary for decision-making but is not always implemented. Health professionals mostly focused on stroke risk assessment, not on the bleeding risk and medication safety issues. (2) Health professionals from different disciplines have different preferences for antithrombotic therapies. Although the majority of health professionals considered warfarin as the first-line therapy, NOACs were preferred by neurologists and haematologists. (3) Health professionals focused on different aspects of the decision making process: GPs and specialists were concerned about the appropriate prescription of antithrombotics, while pharmacists and nurses focused on daily medication management by patients. Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.
引用
收藏
页码:985 / 995
页数:11
相关论文
共 50 条
  • [41] Non-Surgical Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
    Friedman, Paul A.
    Holmes, David R.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2011, 22 (10) : 1184 - 1191
  • [42] Progress for Stroke Prevention With Atrial Fibrillation Emergence of Alternative Oral Anticoagulants
    Katsnelson, Michael
    Sacco, Ralph L.
    Moscucci, Mauro
    STROKE, 2012, 43 (04) : 1179 - 1185
  • [43] Progress for Stroke Prevention With Atrial Fibrillation Emergence of Alternative Oral Anticoagulants
    Katsnelson, Michael
    Sacco, Ralph L.
    Moscucci, Mauro
    CIRCULATION, 2012, 125 (12) : 1577 - 1583
  • [44] Which drug should we use for stroke prevention in atrial fibrillation?
    Lau, Yee C.
    Lip, Gregory Y. H.
    CURRENT OPINION IN CARDIOLOGY, 2014, 29 (04) : 293 - 300
  • [45] Who Gets Stroke Prevention? Stroke Prevention in Atrial Fibrillation Patients in the Inpatient Setting
    Gallagher, Robyn
    Roach, Kellie
    Sadler, Leonie
    Belshaw, Julie
    Kirkness, Ann
    Zhang, Ling
    Proctor, Ross
    Neubeck, Lis
    HEART LUNG AND CIRCULATION, 2015, 24 (05) : 488 - 494
  • [46] Stroke Prevention in Atrial Fibrillation: Where are We Now?
    Ahmad, Yousif
    Lip, Gregory Y. H.
    CLINICAL MEDICINE INSIGHTS-CARDIOLOGY, 2012, 6 : 65 - 78
  • [47] Atrial Fibrillation: Stroke Prevention in Clinical Practice Physician
    Serdechnaya, E. V.
    Yurieva, S. V.
    KARDIOLOGIYA, 2015, 55 (12) : 36 - 41
  • [48] Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation
    Swaans, M. J.
    Post, M. C.
    Rensing, B. J. W. M.
    Boersma, L. V. A.
    NETHERLANDS HEART JOURNAL, 2012, 20 (04) : 161 - 166
  • [49] Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review
    O'Neill, Elizabeth S.
    Grande, Stuart W.
    Sherman, Ariel
    Elwyn, Glyn
    Coylewright, Megan
    AMERICAN HEART JOURNAL, 2017, 191 : 1 - 11
  • [50] Shared Decision-Making for Anticoagulation in Atrial Fibrillation: Do Physicians Really Listen?
    Siegal, Deborah M.
    Healey, Jeff S.
    CANADIAN JOURNAL OF CARDIOLOGY, 2020, 36 (04) : 459 - 461